3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
9
Phase NA
3
Phase 1/2
3
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
108
Gastrointestinal
108
CNS
8
Gynecologic
6
Endocrine
5
Head & Neck
3
Genitourinary
3
Other hematologic neoplasm
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Other
1
NET
1
Classical hematology
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
2265
Lung Neoplasms
1049
Small Cell Lung Carcinoma
403
Adenocarcinoma of Lung
155
Mesothelioma, Malignant
120
Breast Neoplasms
110
Neoplasms
106
Brain Neoplasms
101
Neoplasm Metastasis
95
Melanoma
72
Mesothelioma
70
NSCLC
69
Colorectal Neoplasms
69
Adenocarcinoma, Bronchiolo-Alveolar
56
Thymoma
53
Pancreatic Neoplasms
52
Ovarian Neoplasms
46
Head and Neck Neoplasms
46
Carcinoma, Renal Cell
43
Carcinoma
39
Stomach Neoplasms
36
Prostatic Neoplasms
36
Sarcoma
35
Esophageal Neoplasms
35
Uterine Cervical Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
34
Adenocarcinoma
34
Pleural Effusion, Malignant
33
Recurrence
27
Urinary Bladder Neoplasms
26
Interventions
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Stromal Tumors
×
Thoracic
×
Clear all
NCT01831726
2017-03-20
SIGNATURE
Novartis
Phase 2
Completed
80 enrolled
9 charts